Skip to main content

Copyright and Access to Taxpayer Funded Research

This is the third post in a series on copyright in medicine. We started off the series with two posts. The first discussed the importance of a NEJM article advocating for the greater use of copyleft licenses in medicine. The second detailed the dubious copyright infringement claims by the authors and owners of the mini-mental state exam. This last post in the series is a call for help maintain a bare minimum of open access to taxpayer funded research.

A new Association of American Publishers (AAP) backed bill titled the “Research Works Act” is threatening the currnet National Institutes of Health (NIH) public access policy. The current NIH policy requires that all final peer-reviewed journal manuscripts that arise from NIH funds be submitted to PubMed Central upon acceptance for publication, and that these papers are accessible to the public on PubMed Central no later than 12 months after publication.

Despite an overly restrictive period of up to 12 months before making these works open to the public, Representatives Carolyn Maloney (D-NY) and Darrell Issa (R-CA) have decided to move forward with a bill that would effectively end open access to work funded by the federal government.  The language of the bill is simple in its destructive power:
"No Federal agency may adopt, implement, maintain, continue, or otherwise engage in any policy, program, or other activity that:  
(1) causes, permits, or authorizes network dissemination of any private-sector research work without the prior consent of the publisher of such work;  

 (2) requires that any actual or prospective author, or the employer of such an actual or prospective author, assent to network dissemination of a private-sector research work (i.e any non-governmental agency like a university). 

Many journalists and bloggers have been up in arms over this issue.  Major outlets including Scientific American, WIRED, and the Atlantic, have had articles lambasting the bill.  So, what can be done?  Michael Eisen from UC Berekely said the following in his blog post:
“It is inexcusable that a simple idea – that no American should be denied access to biomedical research their tax dollars paid to produce – could be scuttled by a greedy publisher who bought access to a member of Congress.” [Referring to political contributions that Dutch publisher Elsevier made to Rep Maloney] 

He goes on to urge his readers to:
“call/write/email/tweet Representative Maloney today, and tell her you support taxpayer access to biomedical research results. Ask her why she wants cancer patients to pay Elsevier $25 to access articles they’ve already paid for. And demand that she withdraw H.R. 3699."
By far the easiest thing anyone reading this post can do is to start off by tweeting Rep Maloney at  either @RepMaloney or @CarolynBMaloney.  I would also strongly encourage you to tweet Rep Issa at @darrellissa, as he proudly proclaims himself to be for "an #OPEN, accessible & uncensored internet" (makes you wonder why he proposes cutting off open access to journal articles).

Deevy Bishop, from BishopBlog, takes it one step further with a call to arms for her academic colleagues:
“We provide the articles for Elsevier journals, and we do a lot of unpaid work reviewing and editing for them. None of us wants to restrict our opportunities for publishing, but these days there are a lot of outlets available. When deciding where to submit a paper, I suspect that most academics, like me, take little notice of who the publisher of a journal is. I focus more on whether the journal has a good editor, my prior experience of publication lags, and whether Open Access is available. But as from now, I shall include publisher in the criteria I adopt, and avoid Elsevier as far as I can. Also, if asked to review for a journal, I’ll check if it is in the Elsevier stable, using this handy website, and if so, I’ll explain why I’m not prepared to review. I suggest that if you are as annoyed as I am by this story, you do likewise, and refuse to engage with Elsevier journals.” 

I probably wouldn't go as far as Deevy Bishop and I don't think it is fair to single out Elsevier, but it does make me think of all the free labor that I willing give to these journals.   A similar option is to take a "don't peer-review articles from non-open access journals" approach as seen in this letter by Michael Ashburner posted on Casey Bergman’s blog.

Lastly, you can make your voice heard also to the the National Science and Technology Council's Task Force on Public Access to Scholarly Publications. There is a Request for Information (RFI) on the Federal Register's website that closes on January 12 (ignore the date on the website, the deadline was extended).  This is not part of the bill, but it is another way to get your voice heard.

If you don’t know what to say for the RFI or in the letters to your representative, look at this link from the Provost of Harvard University, Alan M. Garber.   Alternatively, you can also just ask for the bare minimum of open access protect as suggested by Stevan Harnad:

(i) the fundee’s revised, accepted refereed final draft 
(ii) of all refereed journal articles (including refereed conference articles) resulting from the funded research must be 
(iii) deposited immediately upon acceptance for publication 
(iv) in the fundee’s institutional repository. 
(v) Access to the deposit must be made gratis OA (online access free for all) immediately (no OA embargo) wherever possible (over 60 % of journals already endorse immediate gratis OA self-archiving).

By Eric Widera (@ewidera)

Addendum: for an excellent round-up of blog posts on this subject go to John Dupuis' blog.


Certainly, research funded by public funds should be freely available to the public. However, the fact is that medical publishing today is a hugely profitable enterprise run by greedy business people and not by professionals interested in advancing scientific discovery or public health. What other business obtains its raw materials at no cost (medical articles, in this case), has a large cadre of unpaid, slave labor at its command (eg, peer reviewers) and then charges the public outlandish fees for the finished product (eg, in some cases >$50 USD for an individual article of from 1 to 15 electronic pages)?

And, with so many competing enterprises of this nature, is it any wonder that medical journals are filled with studies of dubious quality and little validity; eg, underpowered trials with diminutive but statistically significant effect sizes? In my opinion -- as a researcher/writer -- 90% of what is published in the medical literature these days is overly biased and cannot be trusted as valid. The editors should hang their heads in shame and the public (professionals and all other consumers of the literature) should make their displeasure known by not scribing to or purchasing such drivel.

Popular posts from this blog

Dying without Dialysis

There is a terrific article in this weeks Journal of Pain and Symptom Management by Fliss Murtagh of King's College in London about the epidemiology of symptoms for patients with advanced renal failure who die without dialysis.  This study is important because while we know that patients with advanced renal failure have a limited life expectancy and the average age of initiation of hemodialysis is increasing, we know little about the alternatives to hemodialysis.  Specifically, we know nothing about symptoms affecting quality of life among patients who elect not to start dialysis (so called "conservative management" - is this the best label?).  This article provides a terrific counterpoint to the article in last years NEJM showing that nursing home residents who initiated hemodialysis tended to die and decline in function (see GeriPal write up here). 

The study authors followed patients with the most advanced form of chronic kidney disease (the new name for renal failu…

The Dangers of Fleet Enemas

The dangers of oral sodium phosphate preparations are fairly well known in the medical community. In 2006 the FDA issued it’s first warning that patients taking oral sodium phosphate preparations are at risk for potential for acute kidney injury. Two years later, over-the-counter preparations of these drugs were voluntarily withdrawn by the manufacturers.  Those agents still available by prescription were given black box warnings mainly due to acute phosphate nephropathy that can result in renal failure, especially in older adults. Despite all this talk of oral preparations, little was mentioned about a sodium phosphate preparation that is still available over-the-counter – the Fleet enema.

Why Oral Sodium Phosphate Preparations Are Dangerous 

Before we go into the risks of Fleet enemas, lets spend just a couple sentences on why oral sodium phosphate preparations carry significant risks. First, oral sodium phosphate preparations can cause significant fluid shifts within the colon …

Language Matters: Podcast with Brian Block and Anna DeForest

One of our first GeriPal posts was titled "Rant on Terminology," by Patrice Villars, NP.  In the spirit of looking back over our first 10 years, here is the opening paragraph to that post:

News Headlines read: Sen. Edward Kennedy loses battle with cancer. Really, he lost? I thought he died from a malignant brain tumor, an “aggressive” brain tumor. The median survival is less than a year for people for his particular tumor. Kennedy was diagnosed in May of 2008. He lived over 15 months after diagnosis. What a loser. He must not have fought hard enough. Huh? I thought he spent most of his life battling for social and health care reform in America. In this week's GeriPal podcast we take a deeper dive into this issue of language and medicine.  We are joined by guests Anna DeForest, MD, MFA, a resident in Neurology at Yale, and Brian Block, MD, a pulmonary critical care fellow at UCSF.  

Anna recently published a paper in the NEJM describing her reaction to hearing terms like, &…